Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Public ClinicalTrials.gov record NCT02735707. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT02735707
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UMC Utrecht
- Other
- Enrollment
- 20,000 participants
Conditions and interventions
Interventions
- ARB + DMX-200 Drug
- Amoxicillin-clavulanate Drug
- Anakinra Drug
- Angiotensin Receptor Blockers Drug
- Angiotensin converting enzyme inhibitor Drug
- Apremilast Drug
- Aspirin Drug
- Baloxavir Marboxil Drug
- Baricitinib Drug
- Ceftaroline Drug
- Ceftriaxone Drug
- Clinician-preferred mechanical ventilation strategy Procedure
- Continuation of therapeutic dose anticoagulation Drug
- Convalescent plasma Biological
- Conventional low dose thromboprophylaxis Drug
- Cysteamine Drug
- Delayed administration of convalescent plasma Biological
- Eritoran Drug
- Extended course macrolide Drug
- Five-days oseltamivir Drug
- Five-days oseltamivir + baloxavir marboxil Drug
- Fixed-duration Hydrocortisone Drug
- Fixed-duration dexamethasone Drug
- Fixed-duration higher dose Hydrocortisone Drug
- Hydroxychloroquine Drug
- Hydroxychloroquine + lopinavir/ritonavir Drug
- Imatinib Drug
- Interferon beta-1a Drug
- Intermediate dose thromboprophylaxis Drug
- Ivermectin Drug
- Local standard venous thromboprophylaxis Drug
- Lopinavir / Ritonavir Drug
- Moxifloxacin or Levofloxacin Drug
- Nirmatrelvir/ritonavir Drug
- Nirmatrelvir/ritonavir + remdesivir Drug
- No Immune Modulator for Influenza Other
- No antiplatelet Other
- No antiviral agent for COVID-19 Other
- No antiviral agent for influenza Other
- No cysteamine Other
- No endothelial modulator Other
- No immune modulation for COVID-19 Other
- No immunoglobulin Other
- No renin-angiotensin system inhibitor Other
- No simvastatin Other
- No systemic corticosteroid Other
- No vitamin C Other
- P2Y12 inhibitor Drug
- Piperacillin-tazobactam Drug
- Protocolised mechanical ventilation strategy Procedure
- Remdesivir Drug
- Sarilumab Drug
- Shock-dependent hydrocortisone Drug
- Simvastatin Drug
- Standard course macrolide Drug
- Ten-days oseltamivir Drug
- Ten-days oseltamivir + baloxavir marboxil Drug
- Therapeutic dose anticoagulation Drug
- Tocilizumab Drug
- Vitamin C Drug
Drug · Procedure · Biological + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 10, 2016
- Primary completion
- Jan 31, 2026
- Completion
- Jan 31, 2028
- Last update posted
- Jul 11, 2024
2016 – 2028
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Florida | Jacksonville | Florida | 32209 | Recruiting |
| Augusta University | Augusta | Georgia | 30912 | Not yet recruiting |
| University of Illinois Health | Chicago | Illinois | 60612 | Recruiting |
| Tulane Medical Center | New Orleans | Louisiana | 70112 | Not yet recruiting |
| University of Michigan | Ann Arbor | Michigan | 48109 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27157-1009 | Not yet recruiting |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | Recruiting |
| Oregon Health and Science University | Portland | Oregon | 97239-3098 | Recruiting |
| University of Pittsburgh Medical Centre | Pittsburgh | Pennsylvania | — | Recruiting |
| Brown University - Rhode Island Hospital | Providence | Rhode Island | 02903 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 397 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02735707, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 11, 2024 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02735707 live on ClinicalTrials.gov.